What is the prevalence of HLA (Human Leukocyte Antigen)-B51 in the normal population?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prevalence of HLA-B51 in the Normal Population

The prevalence of HLA-B51 in the normal population varies significantly by ethnicity, ranging from less than 1% in some African populations to 10-15% in Han Chinese populations. 1

Geographic and Ethnic Variation

  • HLA-B51 prevalence shows marked geographic distribution that follows ancient trading routes, particularly the Silk Road, with higher prevalence in regions between the Mediterranean basin and East Asia 2
  • In Caucasian populations, HLA-B51 prevalence is approximately 5-8% 1
  • In African and Asian populations, prevalence is generally lower at <1% 1
  • In African American populations, prevalence is approximately 2.5% 1
  • Han Chinese populations show higher prevalence rates of 10-15% 1

Clinical Significance of HLA-B51

  • HLA-B51 is strongly associated with Behçet's disease, with a pooled odds ratio of 5.78 (95% CI 5.00-6.67) for developing the disease compared to non-carriers 3
  • The association between HLA-B51 and Behçet's disease is consistent across different ethnic populations, supporting its role as a primary risk determinant 3
  • The population-attributable risk for Behçet's disease related to HLA-B51 is estimated at 32-52% across various geographic areas 3
  • In recent studies from the United Arab Emirates, 84% of Behçet's disease patients were HLA-B51 positive 4

Interesting Epidemiological Observations

  • Some indigenous Amerindian populations have high HLA-B51 prevalence but no reported cases of Behçet's disease, suggesting that additional genetic or environmental factors are necessary for disease development 2
  • HLA-B51 shows epistatic interaction with endoplasmic reticulum aminopeptidase (ERAP1), which may explain some of the variability in disease association across populations 5
  • In moyamoya disease, HLA-B51 has been identified as one of several HLA antigens associated with the condition, particularly in patients over 10 years of age 1

Testing and Clinical Applications

  • HLA-B51 testing is not routinely recommended as a screening test for the general population 6
  • In patients with suspected Behçet's disease, HLA-B51 testing may provide supportive diagnostic information, though it is not included in the primary diagnostic criteria 7
  • The strength of association between HLA-B51 and Behçet's disease varies according to sex, suggesting an interaction between this allele and disease characteristics 3

Understanding the prevalence of HLA-B51 in different populations is important for interpreting test results and assessing disease risk, particularly for conditions like Behçet's disease where this genetic marker plays a significant role in pathogenesis.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Consequences of Non-Compliance in HLA-B51 Associated Diseases

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Behçet's Disease Characteristics and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.